Rallybio Corp
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
RLYB$15.66-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders' Equity
| COMMON · ADDITIONALPAID-INCAPITAL · ACCUMULATEDDEFICIT · ACCUMULATED OTHERCOMPREHENSIVEGAIN (LOSS) · STOCKHOLDERS'EQUITY | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · SHARES · AMOUNT | ||||||
| December 31, 2023 | 4,728,674 | $4 | $341,410 | $(235,245) | $15 | $106,184 |
| Issuance of common stock from a securities purchase agreement, net of offering costs of $268 | 454,545 | — | 5,137 | — | — | 5,137 |
| Issuance of common stock under the stock purchase plan | 7,603 | — | 62 | — | — | 62 |
| Issuance of common stock under the stock award plan | 241 | — | — | — | — | — |
| Forfeiture of restricted common stock | (2,320) | — | — | — | — | — |
| Share-based compensation | — | — | 7,993 | — | — | 7,993 |
| Net loss | — | — | — | (57,775) | — | (57,775) |
| Other comprehensive gain | — | — | — | — | 53 | 53 |
| Balance, December 31, 2024 | 5,188,743 | $4 | $354,602 | $(293,020) | $68 | $61,654 |
| Issuance of common stock under the stock purchase plan | 7,258 | $— | $16 | $— | $— | $16 |
| Issuance of common stock under the stock award plan | 87,320 | — | — | — | — | — |
| Share-based compensation | — | — | 5,314 | — | — | 5,314 |
| Net loss | — | — | — | (8,978) | — | (8,978) |
| Other comprehensive loss | — | — | — | — | (50) | (50) |
| Balance, December 31, 2025 | 5,283,321 | $4 | $359,932 | $(301,998) | $18 | $57,956 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.